What is CereVasc?
CereVasc is a specialized medical technology firm dedicated to transforming the treatment of neurological conditions through minimally invasive, endovascular solutions. Its flagship innovation, the eShunt System, is engineered to address the limitations of traditional surgical interventions for communicating hydrocephalus. By utilizing a percutaneous transvenous-transdural approach, the device offers a less traumatic alternative for patients, effectively bridging the gap between complex neurosurgery and modern endovascular techniques. As a clinical-stage entity, CereVasc operates at the intersection of high-stakes medical research and commercial-grade device manufacturing, positioning itself as a critical player in the neuro-interventional market. The company's focus on patient-centric, minimally invasive outcomes aligns with broader industry trends favoring reduced recovery times and improved clinical efficacy in central nervous system care.
How much funding has CereVasc raised?
CereVasc has raised a total of $198.9M across 3 funding rounds:
Series A
$43.9M
Series B
$70M
Series C
$85M
Series A (2020): $43.9M with participation from ATON Partners LLC and Perceptive Xontogeny Venture Fund
Series B (2024): $70M led by Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund
Series C (2026): $85M supported by Piper Sandler and Johnson & Johnson Innovation
Key Investors in CereVasc
Piper Sandler
A prominent investment bank and institutional securities firm providing comprehensive advisory, capital raising, and restructuring services across the healthcare and life sciences sectors.
Johnson & Johnson Innovation
The innovation arm of a global healthcare leader, focused on partnering with early-stage companies to develop transformational medical devices and pharmaceutical solutions.
Bain Capital Life Sciences
A specialized investment firm that provides strategic capital and operational expertise to companies developing innovative therapies and medical technologies.
What's next for CereVasc?
With the successful closure of this latest financing round, CereVasc is poised to transition into a more advanced phase of clinical validation and regulatory engagement. The strategic capital will likely be deployed to scale manufacturing capabilities, expand clinical trial sites, and refine the delivery components of the eShunt System. As the company moves closer to potential commercialization, the focus will shift toward securing regulatory approvals and establishing the clinical evidence necessary for widespread adoption in the neurosurgical community. Investors are closely monitoring the company's ability to navigate the complex regulatory environment while maintaining its technological edge in the competitive medical device sector. The long-term objective remains the establishment of the eShunt System as the standard of care for communicating hydrocephalus, potentially disrupting the existing surgical market and creating significant value for stakeholders.
See full CereVasc company page
